ReviewClinical cardiology2026
Temporal Trends and Disparities in Hypertension-Related Cardiomyopathy Mortality in the United States, 1999-2023.
Review in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension and cardiomyopathy are major contributors of cardiovascular morbidity in the United States. This study investigates long-term mortality trends and disparities in hypertension-related cardiomyopathy from 1999 to 2023 in the United States.
methodsMortality data from CDC WONDER (1999-2023) were evaluated for cardiomyopathy (ICD-10 I42, I42.2, and I42.9) as the primary cause of death and hypertension (ICD-10 I10, I15.0 and I15.9) as a contributing cause among individuals aged ≥ 25 years. Age-adjusted mortality rates (AAMRs) were standardized to the United States 2000 population. Joinpoint regression estimated annual percent change (APC) with 95% confidence intervals.
resultsBetween 1999 and 2023, 153 563 deaths were identified. AAMR increased from 1.26 per 100 000 in 1999 to 2.22 in 2023, driven by a significant early rise from 1999 to 2001 (APC: +30.33; p < 0.005). Males had higher mortality than females (2.98 vs. 1.61) with males declining significantly from 2001 to 2023 (APC: -0.64; p < 0.005). NH Black individuals had the highest AAMR (10.81), followed by NH White individuals (5.02). Mortality was higher in non-metropolitan than metropolitan areas (2.71 vs. 2.26), both declining significantly after 2001 (APC: -0.89; -1.69; p < 0.005). South had the highest burden (AAMR: 4.86), while the Midwest rose significantly after 2017 (APC: +4.11; p < 0.005). Adults aged ≥ 85 years had the highest mortality (CMR: 32.79) increasing significantly after 2015 (APC: +2.44 p < 0.005).
conclusionHypertension-related cardiomyopathy mortality rose sharply in 1999-2001 before declining through 2023, with persistent disparities by sex, race, geography, and age. Targeted hypertension control and equitable cardiovascular care remain needed to reduce this burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.